Dr Herzberg on Future Research Directions in KRAS-Mutant NSCLC

FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025.

Dr Herzberg on Future Research Directions in KRAS-Mutant NSCLC

Benjamin Herzberg, MD, discusses unanswered questions regarding the role of KRAS inhibitors for patients with non–small cell lung cancer.

FDA Greenlights VS-7375 Study for Tough-to-Treat KRAS G12D Tumors

With the clearance of an investigational new drug application from the FDA, a phase 1/2a study will evaluate VS-7375 in KRAS G12D-mutant solid tumors.

FDA Clears IND for VS-7375 in KRAS 612D-Mutated Advanced Solid Tumors

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-612D mutation.